Applied DNA Sciences (APDN) Stock Price, News & Analysis

Company Overview

Applied DNA Sciences, Inc., a biotechnology company, develops and commercializes technologies to produce and detect deoxyribonucleic acid (DNA) in the Americas, Europe, Asia, and internationally. It operates through three segments: Therapeutic DNA Production Services; MDx Testing Services; and DNA Tagging and Security Products and Services. The Therapeutic DNA Production Services segment develops and commercializes the LinearDNA platform, which enables a cell-free manufacture of high-fidelity synthetic DNA sequences for use in nucleic acid-based therapeutics. The MDx Testing Services segment provides clinical molecular diagnostics (MDx) testing and clinical laboratory testing services; COVID-19 testing services, including test scheduling, sample collection, and automated results reporting for higher education institutions, private clients, and businesses under the safeCircle trademark; polymerase chain reaction (PCR) for production and detection of DNA and RNA; and MDx test kits and related supplies, as well as Isotopic analysis testing services. The DNA Tagging and Security Products and Services segment offers SigNature Molecular Tags, which provides a methodology to authenticate goods within large and complex supply chains for materials, such as cotton, nutraceuticals, and other products; SigNify portable DNA readers and SigNify consumable reagent test kits; and fiberTyping, which uses PCR-based DNA detection to detect a product's naturally occurring DNA sequences for the purposes of product provenance authentication and supply chain security. The company was formerly known as Datalink Systems, Inc. and changed its name to Applied DNA Sciences, Inc. in 2002. Applied DNA Sciences, Inc. was founded in 1983 and is headquartered in Stony Brook, New York.

Key Stats

• Today's Range: $0.17 to $0.17
• 50-Day Range: $0.15 to $0.25
• 52-Week Range: $0.12 to $14.40
• Volume: 467,927 shs
• Average Volume: 3.25 million shs
• Market Capitalization: $9.33 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $1.50
• Consensus Rating: Buy

Applied DNA Sciences Stock Analysis - MarketRank™

Applied DNA Sciences scored higher than 30% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Applied DNA Sciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Applied DNA Sciences has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Applied DNA Sciences is -0.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Applied DNA Sciences is -0.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Applied DNA Sciences has a P/B Ratio of 0.59. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

12.79% of the outstanding shares of Applied DNA Sciences have been sold short.

Short Interest Ratio / Days to Cover

Applied DNA Sciences has a short interest ratio ("days to cover") of 1.2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Applied DNA Sciences has recently increased by 40.36%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Applied DNA Sciences does not currently pay a dividend.

Dividend Growth

Applied DNA Sciences does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

12.79% of the outstanding shares of Applied DNA Sciences have been sold short.

Short Interest Ratio / Days to Cover

Applied DNA Sciences has a short interest ratio ("days to cover") of 1.2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Applied DNA Sciences has recently increased by 40.36%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: 0.00

News Coverage This Week

MarketBeat has tracked 2 news articles for Applied DNA Sciences this week, compared to 1 article on an average week.

Search Interest

8 people have searched for APDN on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.

MarketBeat Follows

Only 2 people have added Applied DNA Sciences to their MarketBeat watchlist in the last 30 days. This is a decrease of -80% compared to the previous 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Applied DNA Sciences insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 0.17% of the stock of Applied DNA Sciences is held by insiders.

Percentage Held by Institutions

Only 22.22% of the stock of Applied DNA Sciences is held by institutions.

APDN Stock Analysis - Frequently Asked Questions

How have APDN shares performed this year?

Applied DNA Sciences' stock was trading at $0.2040 at the beginning of the year. Since then, APDN shares have decreased by 16.7% and is now trading at $0.17.
View the best growth stocks for 2025 here.

How were Applied DNA Sciences' earnings last quarter?

Applied DNA Sciences, Inc. (NASDAQ:APDN) issued its quarterly earnings data on Tuesday, December, 17th. The technology company reported ($0.32) earnings per share for the quarter, topping analysts' consensus estimates of ($0.33) by $0.01. Applied DNA Sciences had a negative net margin of 203.76% and a negative trailing twelve-month return on equity of 111.18%.

When did Applied DNA Sciences' stock split?

Applied DNA Sciences's stock reverse split before market open on Thursday, April 25th 2024. The 1-20 reverse split was announced on Thursday, April 25th 2024. The number of shares owned by shareholders was adjusted after the market closes on Thursday, April 25th 2024. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

Who are Applied DNA Sciences' major shareholders?

Applied DNA Sciences' top institutional shareholders include Belvedere Trading LLC.
View institutional ownership trends.

How do I buy shares of Applied DNA Sciences?

Shares of APDN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Applied DNA Sciences own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Applied DNA Sciences investors own include Zomedica (ZOM), Jumia Technologies (JMIA), Nano Dimension (NNDM), NIO (NIO), Virgin Galactic (SPCE), AST SpaceMobile (ASTS) and Advanced Micro Devices (AMD).

Company Calendar

• Last Earnings: 12/17/2024
• Today: 2/05/2025
• Next Earnings (Estimated): 2/13/2025
• Fiscal Year End: 9/30/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Industrial Products
• Industry: Testing laboratories
• Sub-Industry: Business Services
• Current Symbol: NASDAQ:APDN
• CUSIP: N/A
• CIK: 744452
• Web: www.adnas.com
• Phone: (631) 240-8800
• Fax: 631-240-8900
• Employees: 70
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $1.50
• High Stock Price Target: $1.50
• Low Stock Price Target: $1.50
• Potential Upside/Downside: +781.8%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($6.96)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-6,990,000.00
• Net Margins: -203.76%
• Pretax Margin: -206.59%
• Return on Equity: -111.18%
• Return on Assets: -57.58%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 3.36
• Quick Ratio: 3.17

Sales & Book Value

• Annual Sales: $3.43 million
• Price / Sales: 2.74
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.29 per share
• Price / Book: 0.59

Miscellaneous

• Outstanding Shares: 55,190,000
• Free Float: 55,095,000
• Market Cap: $9.39 million
• Optionable: Optionable
• Beta: 0.37